John Zajecka, MD

Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois; Psychiatric Medicine Associates, LLC, Skokie, Illinois

  • 20Articles
  • 85.5KReads1
  • 1997–2026Active
  • 88Collaborators
  • 144Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

John Zajecka, MD, is affiliated with the Department of Psychiatry and Behavioral Sciences at Rush University Medical Center and Psychiatric Medicine Associates, LLC. With publications spanning from 1997 to 2026, Dr. Zajecka has contributed extensively to research on major depressive disorder, treatment-resistant depression, anxiety, anxiolytics, sexual dysfunction, and suicide. His work includes studies on vagus nerve stimulation, esketamine, onfasprodil, nefazodone, and mirtazapine, focusing on treatment efficacy, tolerability, and management of residual symptoms. He has frequently collaborated with noted psychiatrists such as David L. Dunner and Madhukar H. Trivedi.

Publications

JCP
Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report
Original Research ▶ Video

Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report

July 8, 2026

Findings suggest that active VNS reduces suicidal ideation (SI) and potentially induces SI remission among participants with chronic TRD and baseline SI.
, , , et al
JCP
Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series
Case Series

Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series

November 3, 2025

Three patients with TRD who had no or partial response to esketamine monotherapy as part of a clinical trial received augmentation with dextromethorphan/bupropion 45 mg/105 mg daily.
, , , et al
JCP
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
Original Research

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

August 6, 2025

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
, , , et al
JCP
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
, , , et al
JCP
Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment
Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

February 1, 2023

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in some patients.
, , , et al
PCC
Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 27, 2013

, ,
JCP
Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 15, 2013

, ,
JCP
Original Research

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

August 15, 2002

, , , et al
JCP
Original Research

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

May 12, 2002

, , , et al
JCP
Article

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

January 1, 2002

, , , et al
JCP
Article

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

January 1, 2002

, ,
JCP
Original Research

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

June 1, 2001

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe